MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Analysts are intrested in these 5 stocks: ( ($TKO) ), ( ($NKE) ), ( ($AMGN) ), ( ($M) ) and ( ($MARA) ). Here is a breakdown ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a ...